Company Description
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs.
The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler.
Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2005 |
| IPO Date | Apr 27, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 79 |
| CEO | Dr. David S. Zaccardelli Pharm.D. |
Contact Details
Address: 3 More London Riverside London, X0 SE1 2RE United Kingdom | |
| Phone | 011-44-0-2032834200 |
| Website | veronapharma.com |
Stock Details
| Ticker Symbol | VRNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001657312 |
| CUSIP Number | 925050106 |
| ISIN Number | US9250501064 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David S. Zaccardelli Pharm.D. | President, Chief Executive Officer and Executive Director |
| Mark W. Hahn | Chief Financial Officer |
| Dr. Kathleen A. Rickard M.D. | Chief Medical Officer |
| Andrew Fisher | General Counsel |
| Victoria Stewart | Director of Communications |
| Matthew Casbon | Vice President of Sales, Marketing and Training |
| Ostra Jewell | Senior Vice President of Human Resources |
| Dr. Tara Rheault M.P.H., Ph.D. | Chief Development Officer |
| Christopher Martin | Chief Commercial Officer |
| Caroline Diaz | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 27, 2024 | 8-K | Current Report |
| May 10, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 9, 2024 | 8-K | Current Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 30, 2024 | 8-K | Current Report |
| Mar 20, 2024 | ARS | Filing |
| Mar 20, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 12, 2024 | 144 | Filing |
| Mar 8, 2024 | PRE 14A | Other preliminary proxy statements |